SG11201807279QA - Binding proteins and methods of use thereof - Google Patents
Binding proteins and methods of use thereofInfo
- Publication number
- SG11201807279QA SG11201807279QA SG11201807279QA SG11201807279QA SG11201807279QA SG 11201807279Q A SG11201807279Q A SG 11201807279QA SG 11201807279Q A SG11201807279Q A SG 11201807279QA SG 11201807279Q A SG11201807279Q A SG 11201807279QA SG 11201807279Q A SG11201807279Q A SG 11201807279QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- san francisco
- boulevard
- kfkwnlt
- south san
- Prior art date
Links
- 108091008324 binding proteins Proteins 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 102000014914 Carrier Proteins Human genes 0.000 title 1
- 241000237502 Ostreidae Species 0.000 abstract 5
- 235000020636 oyster Nutrition 0.000 abstract 5
- 241000283690 Bos taurus Species 0.000 abstract 2
- 241000699802 Cricetulus griseus Species 0.000 abstract 2
- 241000282577 Pan troglodytes Species 0.000 abstract 2
- 241000532838 Platypus Species 0.000 abstract 2
- 102000023732 binding proteins Human genes 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 abstract 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662316516P | 2016-03-31 | 2016-03-31 | |
PCT/US2017/020654 WO2017172260A1 (fr) | 2016-03-31 | 2017-03-03 | Protéines de liaison et leurs procédés d'utilisation |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201807279QA true SG11201807279QA (en) | 2018-09-27 |
Family
ID=59966343
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201807279QA SG11201807279QA (en) | 2016-03-31 | 2017-03-03 | Binding proteins and methods of use thereof |
Country Status (19)
Country | Link |
---|---|
US (3) | US10174119B2 (fr) |
EP (1) | EP3436068A4 (fr) |
JP (2) | JP7021099B2 (fr) |
KR (2) | KR102370762B1 (fr) |
CN (2) | CN109715206B (fr) |
AU (2) | AU2017241161B2 (fr) |
BR (1) | BR112018068898A2 (fr) |
CA (1) | CA3016035A1 (fr) |
CL (1) | CL2018002687A1 (fr) |
CO (1) | CO2018009995A2 (fr) |
IL (1) | IL261666B1 (fr) |
MX (1) | MX2018011503A (fr) |
MY (1) | MY194669A (fr) |
NZ (1) | NZ745635A (fr) |
PE (1) | PE20190126A1 (fr) |
PH (1) | PH12018501882A1 (fr) |
SG (1) | SG11201807279QA (fr) |
TW (1) | TWI815793B (fr) |
WO (1) | WO2017172260A1 (fr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20190126A1 (es) | 2016-03-31 | 2019-01-17 | Ngm Biopharmaceuticals Inc | Proteinas de union y metodos de uso de las mismas |
WO2018071493A1 (fr) * | 2016-10-12 | 2018-04-19 | Janssen Biotech, Inc. | Procédés de criblage de modulateurs d'une activité biologique de type gdf15 |
WO2020031149A2 (fr) * | 2018-08-10 | 2020-02-13 | Novartis Ag | Domaines extracellulaires gfral et procédés d'utilisation |
US20220127316A1 (en) * | 2019-02-05 | 2022-04-28 | The Trustees Of The University Of Pennsylvania | Peptide Ligands of the Gdnf Family Receptor A-Like (Gfral) Receptor |
US20220213187A1 (en) * | 2019-05-08 | 2022-07-07 | Agilvax Inc. | Compositions and methods related to xct antibodies |
US20220296707A1 (en) * | 2019-06-04 | 2022-09-22 | Regents Of The University Of Minnesota | Anti-opioid compounds and methods of making and using same |
WO2021050978A1 (fr) * | 2019-09-11 | 2021-03-18 | University Of Cincinnati | Traitement de maladies bulleuses cutanées à l'aide d'anticorps |
US20230295307A1 (en) | 2020-06-04 | 2023-09-21 | Daegu Gyeongbuk Institute Of Science And Technology | Gfral-antagonistic antibody and use thereof |
KR20210150981A (ko) | 2020-06-04 | 2021-12-13 | 재단법인대구경북과학기술원 | Gfral 길항 항체 및 이의 용도 |
WO2022178416A1 (fr) * | 2021-02-22 | 2022-08-25 | Northwestern University | Anticorps monoclonaux anti-cd73 |
MX2023011655A (es) | 2021-03-31 | 2023-10-11 | Cambridge Entpr Ltd | Inhibidores terapeuticos de la se?alizacion de gdf15. |
WO2022207785A1 (fr) * | 2021-03-31 | 2022-10-06 | Kymab Limited | Anticorps dirigés contre gfral |
CA3225972A1 (fr) * | 2021-06-30 | 2023-01-05 | Shanghai Jmt-Bio Technology Co., Ltd. | Anticorps anti-gfral et application associee |
AU2022328390A1 (en) | 2021-08-10 | 2024-03-21 | Adimab, Llc | Anti-gdf15 antibodies, compositions and uses thereof |
TW202313694A (zh) | 2021-09-10 | 2023-04-01 | 美商恩格姆生物製藥公司 | 治療癌症以及腫瘤相關之體重減輕及惡病質之方法 |
WO2023048425A1 (fr) * | 2021-09-24 | 2023-03-30 | 재단법인대구경북과학기술원 | Anticorps antagoniste gfral ayant une affinité améliorée, et son utilisation |
KR20230044121A (ko) | 2021-09-24 | 2023-04-03 | 재단법인대구경북과학기술원 | 친화도가 개선된 gfral 길항 항체 및 이의 용도 |
WO2023122213A1 (fr) | 2021-12-22 | 2023-06-29 | Byomass Inc. | Ciblage d'une référence croisée de la voie gdf15-gfral vers applications associées |
WO2023150677A2 (fr) * | 2022-02-03 | 2023-08-10 | Igm Biosciences, Inc. | Molécules de liaison anti-cd38 et leurs utilisations |
WO2023154953A1 (fr) | 2022-02-14 | 2023-08-17 | Ngm Biopharmaceuticals, Inc. | Polypeptides gdf15 pour le traitement et la prévention de maladies auto-immunes |
WO2023192798A2 (fr) * | 2022-03-28 | 2023-10-05 | Coherus Biosciences, Inc. | Compositions anti-ilt4 et méthodes |
Family Cites Families (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5194596A (en) | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
US5350836A (en) | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
WO1994003599A1 (fr) | 1992-08-04 | 1994-02-17 | Sagami Chemical Research Center | ADNc HUMAIN ET PROTEINE POUR LAQUELLE CODE CET ADNc |
US6180602B1 (en) | 1992-08-04 | 2001-01-30 | Sagami Chemical Research Center | Human novel cDNA, TGF-beta superfamily protein encoded thereby and the use of immunosuppressive agent |
JPH07258293A (ja) | 1994-03-23 | 1995-10-09 | Asahi Chem Ind Co Ltd | 新規な蛋白質ならびにその製造方法 |
AU1830195A (en) | 1994-12-15 | 1996-07-03 | Human Genome Sciences, Inc. | Prostatic growth factor |
US6521227B1 (en) | 1999-11-18 | 2003-02-18 | Peter L. Hudson | Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides |
US5994102A (en) | 1994-12-15 | 1999-11-30 | Human Genome Sciences, Inc. | Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides |
ES2324433T3 (es) | 1995-06-22 | 2009-08-06 | St Vincent's Hospital Sydney Limited | Tgf-beta novedoso similar a citocina. |
US6696259B1 (en) | 1995-11-13 | 2004-02-24 | Licentia Ltd. | Assays using glial cell line-derived neurotrophic factor receptors |
KR19990067508A (ko) | 1995-11-13 | 1999-08-25 | 한누 사리올라 | 신경교 세포주 유래 신경영양성 인자 수용체 |
US6524802B1 (en) | 1996-03-29 | 2003-02-25 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-14 |
KR20000038040A (ko) | 1996-09-11 | 2000-07-05 | 오르토-맥네일 파마슈티칼 인코퍼레이티드 | 전립선 암을 치료하기 위한 tnf-베타-형 단백질, 및 관련 핵산 분자, 약제학적 조성물 및 방법 |
WO1998050554A2 (fr) | 1997-05-06 | 1998-11-12 | Human Genome Sciences, Inc. | POLYNUCLEOTIDES ET POLYPEPTIDES D'$i(ENTEROCOCCUS FAECALIS) |
EP1007072A4 (fr) | 1997-05-22 | 2002-06-26 | Cephalon Inc | Recepteurs du facteur neurotrophique derive de lignes de cellules gliales |
AU8591198A (en) | 1997-07-31 | 1999-02-22 | Johns Hopkins University School Of Medicine, The | Growth differentiation factor-15 |
EP1100822A1 (fr) | 1998-07-23 | 2001-05-23 | Smithkline Beecham Corporation | Proteine-6 riche en cysteine secretee (scrp)-6 |
AU5994099A (en) | 1998-10-01 | 2000-04-26 | Urmas Arumae | A novel ret-independent signaling pathway for gdnf |
US6905817B1 (en) | 1998-10-01 | 2005-06-14 | Licestia Ltd. | Ret-independent signaling pathway for GDNF |
US6465181B2 (en) | 1999-03-25 | 2002-10-15 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the prostate |
US6974684B2 (en) | 2001-08-08 | 2005-12-13 | Curagen Corporation | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
JP2002543841A (ja) | 1999-05-17 | 2002-12-24 | バイオファーム ゲゼルシャフト ツア バイオテクノロジシェン エントヴィックルング ウント ツム フェルトリーブ フォン ファルマカ エムベーハー | TGF−βスーパーファミリーの新規のメンバーであるGDF―15の神経保護特性 |
US6866851B1 (en) | 1999-12-28 | 2005-03-15 | Washington University | GFRα1-RET specific agonists and methods therefor |
CA2405709A1 (fr) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Proteines fusionnees a l'albumine |
EP1914554B1 (fr) | 2000-04-20 | 2010-06-09 | St Vincent's Hospital Sydney Limited | Analyseur de diagnostic impliquant la cytokine-1 (MIC-1) inhibitrice des macrophages |
AU2001288770A1 (en) | 2000-09-08 | 2002-03-22 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | A non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties |
US7276593B2 (en) | 2000-12-29 | 2007-10-02 | Curagen Corporation | Proteins and nucleic acids encoding same |
TWI329129B (en) | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
US7511121B2 (en) | 2001-03-09 | 2009-03-31 | Arnason Barry G W | Polymeric immunoglobulin fusion proteins that target low-affinity Fcγreceptors |
EP1921088B1 (fr) | 2001-05-11 | 2014-10-08 | Amgen Inc. | Peptides et molécules associées qui sont liées à tall-1 |
GB0115195D0 (en) | 2001-06-21 | 2001-08-15 | Bae Systems Plc | Split-pin drill jig |
US20030053431A1 (en) | 2001-09-10 | 2003-03-20 | Lila Madour | Method for performing handoff in a radio telecommunications network |
CA2471363C (fr) | 2001-12-21 | 2014-02-11 | Human Genome Sciences, Inc. | Proteines hybrides d'albumine |
US20060253913A1 (en) | 2001-12-21 | 2006-11-09 | Yue-Jin Huang | Production of hSA-linked butyrylcholinesterases in transgenic mammals |
JP2005518820A (ja) | 2002-03-05 | 2005-06-30 | ジェネンテック・インコーポレーテッド | Gdnfrと配列類似性を有する新規ポリペプチド及びこれをコードする核酸 |
US20100285016A1 (en) | 2002-03-05 | 2010-11-11 | Genentech, Inc. | PRO34128 nucleic acids |
US7576185B2 (en) * | 2002-03-05 | 2009-08-18 | Genentech, Inc. | PRO34128 antibodies |
US7919084B2 (en) | 2002-06-17 | 2011-04-05 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
US7157235B2 (en) | 2002-06-17 | 2007-01-02 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
CN1241946C (zh) | 2002-07-01 | 2006-02-15 | 美国福源集团 | 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白 |
JP2006505617A (ja) | 2002-11-08 | 2006-02-16 | バーンズ − ジューウィッシュ・ホスピタル | 前立腺上皮細胞分化のための方法および組成物 |
US7348004B2 (en) | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
LT2380911T (lt) * | 2003-11-05 | 2018-07-10 | Roche Glycart Ag | Antigeną surišančios molekulės, pasižyminčios padidintu fc receptoriaus surišimo afiniškumu ir efektoriaus funkcija |
CN1241941C (zh) * | 2003-11-21 | 2006-02-15 | 中国科学院上海生命科学研究院 | 一种促进神经分化和抗细胞凋亡的蛋白质及其编码基因 |
WO2005099746A1 (fr) | 2004-04-13 | 2005-10-27 | St Vincent's Hospital Sydney Limited | Procede pour la modulation de l'appetit |
WO2005113585A2 (fr) | 2004-05-20 | 2005-12-01 | Acceleron Pharma Inc. | Superfamille des polypeptides tgf-beta modifiés et procédés atenants |
NZ560504A (en) | 2005-01-24 | 2009-07-31 | Pepscan Systems Bv | Binding compounds, immunogenic compounds and peptidomimetics |
WO2007030930A1 (fr) | 2005-09-13 | 2007-03-22 | National Research Council Of Canada | Methodes et compositions permettant de moduler l'activite des cellules tumorales |
EP2004683B1 (fr) | 2006-03-24 | 2016-05-11 | Biogen Hemophilia Inc. | Protéine pc5 utilisée comme enzyme de traitement du propeptide du facteur ix |
US8974748B2 (en) | 2007-04-05 | 2015-03-10 | Corning Incorporated | Dual inlet microchannel device and method for using same |
US20090288176A1 (en) | 2006-04-19 | 2009-11-19 | Genentech, Inc. | Novel Gene Disruptions, Compositions and Methods Relating Thereto |
US7754689B2 (en) | 2006-06-02 | 2010-07-13 | Wyeth Llc | Finger-1 peptide analogs of the TGF-β superfamily |
EP2052253A2 (fr) | 2006-07-26 | 2009-04-29 | Pepscan Systems B.V. | Composés immunogènes |
CN106018820B (zh) | 2006-08-04 | 2018-04-27 | 汉诺威医学院 | 根据gdf-15评价心脏介入风险的工具与方法 |
AU2007309229B8 (en) * | 2006-10-19 | 2013-05-09 | Genentech, Inc. | Anti-Notch3 agonist antibodies and their use in the treatment of Notch3-related diseases |
DK2144639T3 (da) | 2007-04-25 | 2012-12-10 | Stem Cells Spin S A | Ny stamcellelinie og anvendelse deraf |
CA2720628A1 (fr) | 2007-07-26 | 2009-01-29 | Novagen Holding Corporation | Proteines de fusion |
US20100278843A1 (en) | 2007-08-16 | 2010-11-04 | St. Vincent's Hospital Sydney Limited | Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity |
JP2011502106A (ja) | 2007-10-09 | 2011-01-20 | セントビンセンツ ホスピタル シドニー リミテッド | マクロファージ阻害性サイトカイン−1を除去又は不活性化して悪液質を治療する方法 |
WO2009052557A1 (fr) | 2007-10-22 | 2009-04-30 | St Vincent's Hospital Sydney Limited | Procédés de pronostic |
EP2235064B1 (fr) | 2008-01-07 | 2015-11-25 | Amgen Inc. | Méthode de fabrication de molécules hétérodimères fc d'anticorps utilisant les effets de conduite électrostatique |
WO2009087190A1 (fr) | 2008-01-08 | 2009-07-16 | Roche Diagnostics Gmbh | Moyens et procédés pour évaluer le risque de patients se présentant à des unités d'urgence sur la base de gdf-15 |
US20100286067A1 (en) | 2008-01-08 | 2010-11-11 | Biogenerix Ag | Glycoconjugation of polypeptides using oligosaccharyltransferases |
US8718994B2 (en) | 2008-04-09 | 2014-05-06 | Transtech Pharma, Llc | Ligands for the GLP-1 receptor and methods for discovery thereof |
JP2011523051A (ja) | 2008-05-20 | 2011-08-04 | エフ.ホフマン−ラ ロシュ アーゲー | 1型糖尿病におけるバイオマーカーとしてのgdf−15 |
WO2010007041A1 (fr) | 2008-07-14 | 2010-01-21 | Roche Diagnostics Gmbh | Panneau multimarqueur pour diagnostiquer, surveiller et sélectionner le traitement destiné à des patients souffrant d'insuffisance cardiaque |
WO2010019263A2 (fr) | 2008-08-15 | 2010-02-18 | Genzyme Corporation | Produits de construction de flt soluble pour traiter des cancers |
CN102203619B (zh) | 2008-10-31 | 2015-12-16 | 圣文森特医院悉尼有限公司 | 慢性肾病中的预测方法 |
MX349178B (es) | 2008-10-31 | 2017-07-17 | Centocor Ortho Biotech Inc | Diferenciación de células madre embrionarias humanas al linaje endocrino pancreático. |
EP2209003A1 (fr) | 2009-01-16 | 2010-07-21 | F. Hoffmann-Roche AG | Moyens et procédés pour différencier la fibrose de la cirrhose |
EP2211182A1 (fr) | 2009-01-16 | 2010-07-28 | Roche Diagnostics GmbH | Procédé pour l'évaluation de la gravité de la cirrhose du foie |
AU2010213575B2 (en) | 2009-02-12 | 2013-11-14 | Stryker Corporation | Peripheral administration of proteins including TGF-beta superfamily members for systemic treatment of disorders and disease |
GB0902737D0 (en) | 2009-02-19 | 2009-04-01 | Univ Gent | GDF15 as a differential marker for spondyloarthropathy |
KR101558642B1 (ko) | 2009-02-24 | 2015-10-12 | 솔크 인스티튜트 포 바이올로지칼 스터디즈 | Tgf-베타 슈퍼패밀리의 설계자 리간드 |
US8188040B2 (en) | 2009-05-05 | 2012-05-29 | Amgen Inc. | FGF21 mutants and uses thereof |
EP2451840B1 (fr) | 2009-07-08 | 2018-12-26 | Amgen Inc. | Conception de molécules fc d'anticorps exemptes d'agrégation et stables par ingénierie de l'interface du domaine ch3 |
WO2011008956A2 (fr) | 2009-07-15 | 2011-01-20 | Zirus, Inc. | Gènes de mammifères impliqués dans une infection |
WO2011050407A1 (fr) | 2009-10-28 | 2011-05-05 | St Vincent's Hospital Sydney Limited | Procédés de diagnostic et de pronostic de polypes du côlon |
SI2496601T1 (sl) | 2009-11-05 | 2017-09-29 | F. Hoffmann-La Roche Ag | Tehnike in sestavek za sekrecijo heterolognih polipeptidov |
WO2011064758A2 (fr) | 2009-11-30 | 2011-06-03 | Pfizer Limited | Protéine de fusion |
JPWO2011105573A1 (ja) | 2010-02-26 | 2013-06-20 | 株式会社 未来創薬研究所 | 抗icam3抗体およびその用途 |
US9212221B2 (en) | 2010-03-03 | 2015-12-15 | Detroit R & D, Inc. | Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses |
JP5791335B2 (ja) | 2010-04-07 | 2015-10-07 | 花王株式会社 | オルガノポリシロキサン化合物の製造方法 |
US20130202564A1 (en) | 2010-04-09 | 2013-08-08 | University Of Southern California | Systems and Methods of Cell Activated, Controlled Release Delivery of Growth Factors for Tissue Repair and Regeneration |
EP2383571A1 (fr) | 2010-05-02 | 2011-11-02 | Prof. Hess Medical Consulting GmbH | Facteur 15 de différentiation de croissance (GDF 15) pour la prédiction des risques d'ulcère de pieds diabétique |
CN103080746B (zh) | 2010-08-26 | 2015-07-15 | 弗·哈夫曼-拉罗切有限公司 | 生物标志物在评估从动脉高血压向心力衰竭的早期转变中的用途 |
WO2012047427A2 (fr) | 2010-08-31 | 2012-04-12 | The Regents Of The University Of California | Anticorps pour neurotoxines botuliques |
EP2439535A1 (fr) | 2010-10-07 | 2012-04-11 | F. Hoffmann-La Roche AG | Diagnostic de maladies cardiaques liées au diabète et GDF-15 et troponine en tant que prédicteurs pour le développement du diabète sucré de type 2 |
US10752664B2 (en) | 2011-04-08 | 2020-08-25 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15) |
ES2608835T3 (es) | 2011-04-13 | 2017-04-17 | Bristol-Myers Squibb Company | Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones |
CA2835242A1 (fr) | 2011-06-30 | 2013-01-03 | Genentech, Inc. | Formulations d'anticorps anti-c-met |
CA2839539C (fr) | 2011-06-30 | 2021-06-08 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide heterodimerise |
WO2013012648A1 (fr) * | 2011-07-15 | 2013-01-24 | Emory University | Gdf15 dans des applications de diagnostic et thérapeutiques |
EP2807266B1 (fr) | 2012-01-26 | 2020-01-15 | Amgen Inc. | Polypeptides du facteur de croissance et de différenciation 15 (gdf-15) |
EP2830646B1 (fr) | 2012-03-27 | 2018-03-07 | NGM Biopharmaceuticals, Inc. | Compositions et méthodes d'utilisation pour le traitement de troubles métaboliques |
EP2863910B1 (fr) | 2012-06-20 | 2020-03-11 | University Of Virginia Patent Foundation | Compositions et procédés pour réguler l'homéostasie du glucose et l'action de l'insuline |
WO2014000042A1 (fr) | 2012-06-27 | 2014-01-03 | Prince Henry's Institute Of Medical Research | Compositions et procédés pour modifier des ligands de la famille du tgf-β |
WO2014011955A2 (fr) * | 2012-07-12 | 2014-01-16 | Abbvie, Inc. | Protéines de liaison à il-1 |
US9493562B2 (en) | 2012-07-19 | 2016-11-15 | Alethia Biotherapeutics Inc. | Anti-Siglec-15 antibodies |
MA20150232A1 (fr) | 2012-08-08 | 2015-07-31 | Roche Glycart Ag | Protéines de fusion de l'interleukine-10 et leurs utilisations |
JO3462B1 (ar) * | 2012-08-22 | 2020-07-05 | Regeneron Pharma | أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها |
TR201910744T4 (tr) | 2012-09-26 | 2019-08-21 | Univ Wuerzburg J Maximilians | Büyüme ve farklılaşma faktörü 15 e (gdf-15) yönelik monoklonal antikorlar. |
US9803014B2 (en) | 2012-10-24 | 2017-10-31 | Research Development Foundation | JAM-C antibodies and methods for treatment of cancer |
WO2014086365A1 (fr) | 2012-12-03 | 2014-06-12 | Rigshospitalet | Anticorps anti-pad2 et traitement de maladies auto-immunes |
DK2934584T3 (da) | 2012-12-21 | 2020-05-18 | Aveo Pharmaceuticals Inc | Anti-gdf15-antistoffer |
DE102013100322A1 (de) | 2013-01-14 | 2014-07-17 | Claas Selbstfahrende Erntemaschinen Gmbh | Schneidwerk |
US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
EP2950807B1 (fr) | 2013-01-30 | 2018-03-28 | NGM Biopharmaceuticals, Inc. | Compositions et procédés à utiliser pour le traitement de troubles métaboliques |
CA2903587C (fr) | 2013-03-15 | 2021-09-28 | Genentech, Inc. | Polypeptides d'il-22 et proteines de fusion fc il-22 et leurs procedes d'utilisation |
WO2014140374A2 (fr) * | 2013-03-15 | 2014-09-18 | Novo Nordisk A/S | Anticorps monovalents anti-cd27 |
US9868777B2 (en) * | 2013-06-10 | 2018-01-16 | Merck Sharp & Dohme Corp. | CMV neutralizing antigen binding proteins |
EA202092386A1 (ru) | 2013-07-31 | 2021-04-30 | Эмджен Инк. | Конструкции на основе фактора дифференцировки и роста 15 (gdf15) |
RU2751660C2 (ru) | 2014-07-21 | 2021-07-15 | Новартис Аг | Лечение злокачественного новообразования с использованием гуманизированного химерного антигенного рецептора против всма |
AP2016009663A0 (en) | 2014-07-30 | 2016-12-31 | Ngm Biopharmaceuticals Inc | Compositions and methods of use for treating metabolic disorders |
EA036985B1 (ru) | 2014-10-31 | 2021-01-25 | НДжМ БИОФАРМАСЬЮТИКАЛЗ, ИНК. | Композиции и способы лечения метаболических расстройств |
GB201512733D0 (en) | 2015-07-20 | 2015-08-26 | Genagon Therapeutics Ab | Therapeutic agents for treating conditions associated with elevated GDF15 |
WO2017121865A1 (fr) | 2016-01-15 | 2017-07-20 | Novo Nordisk A/S | Récepteur de mic-1 et utilisations correspondantes |
JP2019510739A (ja) | 2016-02-29 | 2019-04-18 | イーライ リリー アンド カンパニー | Gfral受容体療法 |
EP3423097A4 (fr) * | 2016-03-04 | 2019-08-21 | NGM Biopharmaceuticals, Inc. | Compositions et procédés pour moduler le poids corporel |
PE20190126A1 (es) * | 2016-03-31 | 2019-01-17 | Ngm Biopharmaceuticals Inc | Proteinas de union y metodos de uso de las mismas |
WO2018071493A1 (fr) | 2016-10-12 | 2018-04-19 | Janssen Biotech, Inc. | Procédés de criblage de modulateurs d'une activité biologique de type gdf15 |
-
2017
- 2017-03-03 PE PE2018001850A patent/PE20190126A1/es unknown
- 2017-03-03 CN CN201780030436.7A patent/CN109715206B/zh active Active
- 2017-03-03 KR KR1020187030069A patent/KR102370762B1/ko active IP Right Grant
- 2017-03-03 JP JP2018548669A patent/JP7021099B2/ja active Active
- 2017-03-03 SG SG11201807279QA patent/SG11201807279QA/en unknown
- 2017-03-03 NZ NZ745635A patent/NZ745635A/en unknown
- 2017-03-03 TW TW106107129A patent/TWI815793B/zh active
- 2017-03-03 MY MYPI2018703041A patent/MY194669A/en unknown
- 2017-03-03 US US15/449,839 patent/US10174119B2/en active Active
- 2017-03-03 BR BR112018068898A patent/BR112018068898A2/pt unknown
- 2017-03-03 CA CA3016035A patent/CA3016035A1/fr active Pending
- 2017-03-03 MX MX2018011503A patent/MX2018011503A/es unknown
- 2017-03-03 KR KR1020227006994A patent/KR102630655B1/ko active IP Right Grant
- 2017-03-03 EP EP17776245.7A patent/EP3436068A4/fr active Pending
- 2017-03-03 AU AU2017241161A patent/AU2017241161B2/en active Active
- 2017-03-03 WO PCT/US2017/020654 patent/WO2017172260A1/fr active Application Filing
- 2017-03-03 CN CN202311479185.4A patent/CN117986363A/zh active Pending
- 2017-03-03 IL IL261666A patent/IL261666B1/en unknown
-
2018
- 2018-09-04 PH PH12018501882A patent/PH12018501882A1/en unknown
- 2018-09-12 US US16/129,438 patent/US10975154B2/en active Active
- 2018-09-21 CO CONC2018/0009995A patent/CO2018009995A2/es unknown
- 2018-09-21 CL CL2018002687A patent/CL2018002687A1/es unknown
-
2021
- 2021-03-05 US US17/194,144 patent/US20220073627A1/en active Pending
-
2022
- 2022-02-03 JP JP2022015851A patent/JP2022088355A/ja active Pending
- 2022-08-31 AU AU2022224794A patent/AU2022224794A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201807279QA (en) | Binding proteins and methods of use thereof | |
SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
SG11201901126UA (en) | Combination therapy for cancer | |
SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
SG11201907427YA (en) | Engineered transferrin receptor binding polypeptides | |
SG11201908280SA (en) | "chimeric molecules and uses thereof" | |
SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
SG11201909963YA (en) | Methods for treating dravet syndrome | |
SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
SG11201906682YA (en) | Glucagon receptor binding proteins and methods of use thereof | |
SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201908238SA (en) | Anti-c5 antibodies and uses thereof | |
SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201810429UA (en) | Anti-cd19 antibody formulations | |
SG11201901597UA (en) | Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof | |
SG11201908456VA (en) | Linker units and molecular constructs comprising same | |
SG11201903012RA (en) | Anti-c1s antibodies and methods of use thereof | |
SG11201907948TA (en) | Formulations comprising pd-1 binding proteins and methods of making thereof |